Active Phase I Trials

 

19131

  • An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-Line Treatment in Cisplatin-ineligible Patients with FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma. (UCD participating in Part A/Phase Ib only)

AMC-095

  • A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Tumors with an Expansion Cohort in HIV Associated Solid Tumors

B7661001

  • A First-In-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors (UCD participating in Dose Escalation, Dose Expansion, and all 3 cohorts)

D419NC00001

  • A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors  (UCD participating in Part 3 ONLY: Colorectal)

HALO-110-101

  • A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

LYC-55716-1001

  • A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer [UCD will be participating in Expansion phase ONLY] [Open Cohorts: H&N and Renal Cell]

M14-006

  • A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects with Advanced Solid Tumors

M15-819

  • A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy, in Subjects with Advanced Solid Tumors (Temporarily Closed)

PHI-70

  • CCRC: Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients with Advanced Solid Tumors (NCI#9127)

PHI-76

  • Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed (NCI #9837)